Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Multiple Sclerosis l: Introduction

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...

Determination of Multiple Dosing Parameters: Loading and Maintenance Doses

Determination of Multiple Dosing Parameters: Loading and Maintenance Doses

A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Sentiment Analysis in Children with Neurodevelopmental Disorders in an Ingroup/Outgroup Setting.

Journal of autism and developmental disorders·2019

Same author

Inpatient surgical treatment of paediatric proximal humerus fractures between 2000 and 2012.

Journal of children's orthopaedics·2018

Same author

The 67P/Churyumov-Gerasimenko observation campaign in support of the Rosetta mission.

Philosophical transactions. Series A, Mathematical, physical, and engineering sciences·2017

Same author

ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle.

Clinical and translational allergy·2017

Same author

Building Bridges for Innovation in Ageing: Synergies between Action Groups of the EIP on AHA.

The journal of nutrition, health & aging·2016

Same author

Integrated care pathways for airway diseases (AIRWAYS-ICPs).

The European respiratory journal·2014

Same journal

Monoclonal antibodies for treatment of osteoporosis.

Drugs of today (Barcelona, Spain : 1998)·2023

Same journal

Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma.

Drugs of today (Barcelona, Spain : 1998)·2023

Same journal

Sugemalimab, a novel PD-L1 inhibitor for treatment of advanced or metastatic non-small cell lung cancer.

Drugs of today (Barcelona, Spain : 1998)·2023

Same journal

Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis.

Drugs of today (Barcelona, Spain : 1998)·2023

Same journal

Mitapivat for sickle cell disease and thalassemia.

Drugs of today (Barcelona, Spain : 1998)·2023

Same journal

Cenegermin for the treatment of dry eye disease.

Drugs of today (Barcelona, Spain : 1998)·2023

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 7, 2026

A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation (tDCS) in Multiple Sclerosis (MS)

A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation (tDCS) in Multiple Sclerosis (MS)

Published on: December 26, 2015

Dalfampridine in multiple sclerosis.

A D Goodman¹, M Hyland

¹Department of Neurology, University of Rochester, Medical Center, Rochester, New York 14642, USA. andrew_goodman@urmc.rochester.edu

Drugs of Today (Barcelona, Spain : 1998)

|October 23, 2010

Summary

This summary is machine-generated.

Dalfampridine (4-aminopyridine) improves walking speed by 25% in over a third of multiple sclerosis patients. This review covers its pharmacology, clinical trials, and safety, including seizure risks.

More Related Videos

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis

Published on: February 28, 2021

Adapted Resistance Training Improves Strength in Eight Weeks in Individuals with Multiple Sclerosis

Adapted Resistance Training Improves Strength in Eight Weeks in Individuals with Multiple Sclerosis

Published on: January 29, 2016

Related Experiment Videos

Last Updated: Jun 7, 2026

A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation (tDCS) in Multiple Sclerosis (MS)

A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation (tDCS) in Multiple Sclerosis (MS)

Published on: December 26, 2015

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis

Published on: February 28, 2021

Adapted Resistance Training Improves Strength in Eight Weeks in Individuals with Multiple Sclerosis

Adapted Resistance Training Improves Strength in Eight Weeks in Individuals with Multiple Sclerosis

Published on: January 29, 2016

Area of Science:

Pharmacology
Clinical Trials
Drug Safety

Background:

Dalfampridine, also known as 4-aminopyridine (4-AP) or fampridine, is a potassium channel blocker.
Multiple sclerosis (MS) is a chronic disease affecting the central nervous system.

Purpose of the Study:

To review the pharmacology, pharmacokinetics, and clinical trial data of dalfampridine in MS patients.
To evaluate the efficacy and safety profile of dalfampridine for improving walking ability in MS.

Main Methods:

Review of early clinical trials and recent phase II and III placebo-controlled trials.
Analysis of data on walking speed improvement and adverse events.

Main Results:

Extended-release dalfampridine demonstrated an average 25% increase in walking speed in over one-third of consistent responders.
The safety profile was reviewed, highlighting the risk of epileptic seizures.

Conclusions:

Dalfampridine shows efficacy in improving walking speed in a subset of MS patients.
Potential risks, such as seizures, must be considered in its clinical use.